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Summary 
The concept of immune surveillance states that the principle defense mechan-
isms against the development of neoplasia consist of certain homeostatic processes 
of the immune system. There now exists considerable opinion to suggest that this 
concept can no longer be sustained in its original form. Nevertheless, strong 
support for a specialized or restricted form of immune surveillance exists in the 
association of both spontaneoLls and induced states of immune deficiency with 
increases in certain types of neoplasia. This relationship is nowhere being better 
exhibited than in the spectrum of lymphoproliferative disorders occurring in 
patients undergoing organ transplantation and subsequent immunosuppression. 
The post-transplant lymphoproliferative disorders following the transplantation 
of kidneys, livers, hearts, heart-lungs and pancreas, and which developed undcr 
cyclosporinc steroid therapy at the University of Pittsburgh Health Center between 
January 1981 and August 31, 1986 were reviewed. A total of 36 (approximate 
incidence of 1.7%) rccipients of various organs were identified as having devcloped 
lympboproliferative disorders from 1 to 160 months following organ transplanta-
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tion. The patients ranged in age from 1 to 62 years (mean 22 years) at the time of 
transplantation with a male: female ratio of 2.6: 1. The mainstay of immunosup-
pressive therapy for almost all patients was cyclosporine (CsA) and steroids. 
Typically, the onset of the disease took place fairly rapidly after transplantation, 
with 19 of the 36 cases occurring in less than 6 months, and 31 of the 36 cases 
occurring within the first year. Serological evidence of active infection with 
Epstein-Barr virus around thc time of the lymphoproliferative disorder was found 
in 33 of 36 patients (92%). It is of note that there were twice as many primary as 
reactivation EBV infections. The relationship of this virus to such lymphoprolifera-
tive disorders has been repeatedly stressed in the literature. 
The clinical presentation may be extremely variable, but the head and neck area 
and the gastrointestinal tract were the most commonly involved regions in our 
senes. 
The instinctive approach to the treatment of these post-transplant lympho-
proliferative disorders would be chemotherapy. However, based on our clinical 
results, a more logical initial therapy appears to be manipulation of the immune 
system. Our results demonstrate that a drastic reduction or even complete 
cessation of immunosuppressive therapy elicits a rapid response in those cases 
amenable to this therapy. Interestingly enough, rejection did not occur in some of 
our cases even if the immunosuppression was reduced to up to 75% of the initial 
dose. Therefore, in practice we generally assess the clinical response to the tumor 
after a 50'10 reduction in immunosuppressive therapy. The remission is usually 
complete and the immunosuppressive regimen may later be resumed at previous or 
slightly reduced levels. The temptation to treat with chemotherapy should be 
resisted since this would further reduce the host immune response, causing an even 
worse exacerbation of the lymphoproliferative disorder. In those monoclonal and 
monomorphous tumors which do not respond to a reasonable trial of reduced 
immunosuppression, aggressive antilymphoma therapy may be unavoidable. In 
practice, these unfortunate patients are usually moribund at the outset, have a very 
rapid downhill course, and often die with multiple infections. Deaths both of 
patients with polyclonal and monoclonal tumors have seemed more related to the 
lateness of diagnosis than to any other factor. Add to this the fact that there is still 
no absolute a priori pathologic indicator of which tumors will and which will not 
respond to host immune restoration in a given patient, and that it is not as yet clear 
at what point, if any, reconstitution of the immune system can no longer switch off 
tumor growth, the case for immunosuppressive dose modulation as an initial 
therapy appears complete. We have presented evidence that polyclonal as well as 
monoclonal tumors remain subject to host control mechanisms if immune function 
is allowed to recover at least partially by a reduction of immunosuppressive 
therapy. The favorable outcome of a large number of these cases in response to 
Control of PTLDs and Kaposi's Sarcoma by Modulation of Immunosuppression 569 
modulation of immunosuppression has raised the challenge of defining both host 
and tumor variables that characterize the mechanisms and limitations of immune 
controls in this system. 
Zusamritenfassung 
Das Konzept der Immunuberwachung geht davon aus, daB die Hauptabwehr-
mechanismen gegen die Entstehung von Krebs bestimmte homoostatische Pro-
zesse im Immunsystem beinhalten. Es mehren sich jedoch Stimmen, daB dieses 
Konzept in seiner ursprunglichen Form nicht Hinger aufrechterhalten werden kann. 
Dennoch gibt cs deutliche Hinwcise fur eine spezielle oder restringierte Form der 
Immunuberwachung im Zusammenhang von spontanen und induzierten lmmun-
defekten mit einer Zunahme von bestimmten Krebsarten. Diese Beziehung zeigt 
sich nirgends bcsser aIs im Spektrum der lymphoproliferativen Erkrankungen, die 
sich bci Patienten nach einer Organtransplantation mit anschlieBcnder Immunsup-
pression einstellen. 
Es wird cine ZusammensteIIung der Iymphoproliferativcn Erkrankungen nach 
Niercn-, Lebcr-, Herz-, Herz-Lungen- und Pankreas-Transplantationen gcgcben, 
die sich im Gesundheitszentrum der Universitat von Pittsburgh in der Zeit von 
Januar 1981 bis Ende August 1986 unter einer Cyc1osporin-Steroid-Therapie 
entwickelten. Bei 36 (ca. 1,7%) Empfangero von verschiedenen Organen wurden 1 
bis 160 Monate nach der Organtransplantation lymphoproliferative Erkrankungen 
nachgcwiesen. Das Lcbensalter der Patienten betrug zum Zeitpunkt der Trans-
plantation 1 bis 62 Jahre (Mittelwert 22 Jahre), das Verhaltnis von Mannern zu 
Frauen 2,6: 1. Fur fast aile Patienten bestand die immunsuppressive Therapie 
vorwiegend aus CycIosporin (CsA) und Steroiden. Typischerweise stellte sich der 
Beginn der Erkrankung recht bald nach der Transplantation ein, bei 19 der 
36 Patienten innerhalb von weniger als 6 Monaten und bei 31 der 36 Patienten 
innerhalb des ersten Jahres. Serologisch konnte eine akute Epstein-Barr-Virusin-
fcktion bei 33 der 36 Patienten (92%) wahrend der Phase der lymphoproliferativen 
Prozesse nachgewiesen werden. Es ist bemerkenswert, daB es doppelt so viele 
Erst- wie EBV-Re-Infektionen gibt. Ein Zusammenhang zwischen diescm Virus 
und lymphoproliferativen Erkrankungen ist in der Literatur wiederholt betont 
worden. 
Das klinische Bild kann extrem variabel sein. aber der Kopf-Hals-Bercich und 
der Gastrointestinaltrakt waren die am haufigsten betroffenen Regionen in 
unserem Patientengut. 
Die nahclicgende Behandlungsmethode dieser nach einer Transplantation 
auftretenden lymphoproliferativen Erkrankungen ware die Chemotherapie. Auf-
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grund unserer klinisehen Ergebnisse scheint jedoch die Manipulation des Immun-
systems besser als Anfangstherapic geeignet zu sein. Unsere Ergebnisse zeigen, 
daB eine drastisehe Einschrankung oder sogar ein totaler Abbruch einer immun-
suppressiven Therapie ein schnelles Ansprechen jener Patienten bewirkt, die einer 
solchcn Therapie zuganglieh sind. Interessanterweise kam es bei einigen Fallen 
sclbst dann nieht zu ciner AbstoBung. wenn die Oosis der Immunsuppressiva bis zu 
75°/" der Anfangsdosis reduziert wurdc. Oeshalb bestimmen wir in der Praxis im 
allgemeinen das klinisehe Anspreehen des Tumors nach einer 50%igen Rcduzie-
rung der immunsuppressiven Therapie. 1m allgemeinen kommt es zu einer 
vollstandigen Remission, und die immunsuppressive Therapic kann spater mit der 
ursprungliehen oder einer Icieht verminderten Dosis wieder aufgenommen wer-
den. Der Yersuehung, Chemotherapie anzuwenden, sollte widerstanden werden, 
da diese die Immunantwort des Wirtes weiter reduzieren und damit sogar zu ciner 
Versehleehterung der Iymphoproliferativen Prozesse fiihren wiirde. Bci solchen 
monoklonalen und monomorphen Tumorcn, die nieht auf einen vernunftigen 
Versuch, die lmmunsuppression zu reduzieren, ansprechen, ist eine aggressive 
Antilymphoma-Therapie wahrscheinlieh nieht zu vermeiden. In der Praxis erwei-
sen sich dicsc ungluckliehen Patienten gew()hnlieh von Anfang an als moribund; es 
geht rapide mit ihnen bergab und sic sterbcn haufig an multiplen Infekten. Oer 
Tod von Patienten mit polyklonalcn wie aueh von soIchen mit monoklonalen 
Tumoren sehien mehr auf die zu spate Diagnose als auf irgendeinen anderen 
Faktor zuruekzufilhren zu sein. Aul3crdem gibt es bis jetzt keinen absolut a priori 
pathologisehen lndikator dafiir, weIche Tumoren auf eine Immunrestoration in 
cinem bestimmtcn Patienten anspreehen und weIche nieht. Es ist bisher nieht klar, 
an welcher Stelle, wenn es uberhaupt cine gibt, eine Rekonstitution des Immun-
systems das Tumorwaehstum nieht Hinger hemmen kann und ob del' Fall fUr eine 
Modulation der immunsuppressiven Dosis als Anfangstherapie geeignet erscheint. 
WiT haben deutlieh gemaeht, daB sowohl polyklonale als aueh monoklonale 
Tumoren den Wirts-Kontroll-Meehanismen untcrworfen bleiben, falls wenigstens 
eine teilwcise Erholung der Immunfunktion mittels Reduzierung der immunsup-
pressiven Therapie ermoglieht wird. Oer gunstigc Verlauf bei einem groBen Teil 
dieser Falle hinsiehtlieh des Ansprechens auf die Modulation der Immunsuppres-
sion hat dazu hcrausgefordert, sowohl die Wirts- als aueh die Tumorvariablcn zu 
definieren. die den Meehanismus und die Grcnzen der Immuniiberwachung in 
diesem System bestimmen. 
Resume 
Le concept de surveillance immunitaire stipule que Ie principal mecanisme de 
defense contrc Ie developpement de neoplasies consiste en une eertaine homeosta-
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sie du systcme immunitaire. Ce concept ne semble plus actuellement etre defendu 
au moins dans sa forme initiale. Cependant, l'association de deficits immunitaires 
spontanes ou induits a l'augmentation de certains types de neoplasies constitue un 
argument important en faveur d'une forme de surveillance immunitaire specialisee 
au restreinte. Cette relation est nulle part mieux demontree que dans Ie spectre des 
desordres Iymphoproliferatifs survenant chez des patients ayant subi une transplan-
tation d'organe suivie d'un traitement immu!10suppresseur. 
Les desordres lymphoproliferatifs survenant apres transplantation de rein, foie, 
ccrur, ccrur-poumon et pancreas, et developpes au cours d'un traitement par la 
cyclosporine et les steroides au Pittsburg Health Center de janvier 1981 a aout 
1 tJ86 ont ete analyses. Au total, 36 transplantes (incidence approximative de 1.7%) 
ont developpe des desordres Iymphoproliferatifs de 1 a 160 mois suivant la 
transplantation. L'age des patients au moment de la transplantation s'echelonnait 
de 1 a 62 ans (moyetme 22 ans) et Ie groupe comportait 2,6 hommes pour J femme. 
La plupart des patients avaient comme traitement immunosuppresseur essen tiel 
la cyclosporine associee aux steroi·des. Dans la plupart des cas, Ie debut de la 
maladie survenait assez rapidement apres la transplantation, en moins de six mois 
dans 19 des 36 cas observes, et en moins d'un an dans 31 cas sur 36. Des preuves 
serologiques d'une infection active par Ie virus d'Epstein Barr ont ete trouvees chez 
33 des 36 patients (92%) au moment de l'apparition du desordre lymphoprolifera-
tif. II faut noter qu'il y aurait deux fois plus d'infections primaires que de 
reactivations d'infections a virus EBY. La relation entre ce virus et de tels 
desordres lymphoproliferatifs a ete sou vent soulignee dans la litterature. 
La forme clinique peut etre extremement variable, mais la region de la tete et du 
cou ainsi que Ie tractus digestif etaient les regions les plus souvent atteintes dans 
notre serie de patients. 
L'approche instinctive du traitement de ces maladies lymphoprolifcratives 
devrait etre la chimiotherapie. Cependant, d'apres nos resultats cIiniques. la 
therapeutique initiale la plus logique semble etre la manipulation du systcme 
imt11unitaire. Nos resultats demontrent qu'une reduction drastique ou meme un 
arret total de la therapeutique immunosuppressive entraine une reponse rapide 
dans les cas ou une telle, reduction est envisageable. 
II faut noter que dans eertains cas, il n'y a pas eu de rejet, meme lorsque 
['immunosuppression ctait reduite de 75% par rapport a la dose initiaIc. En 
pratique, nous controlons en general la reponse cIinique apres une reduction de 
50% de la therapeutique immunosuppressive. La remission est en general 
complete et la therapeutique immunosuppressive peut etre ensuite reprise aux 
doses anterieures ou legerement plus faibles. La tentation de traiter ces patients 
par une chimiothCrapie doit etre surmontee car ce traitement reduirait encore les 
defenses immunitaires de l'hote, entrainant meme une aggravation du desordre 
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lymphoproliferatif. Au cours de ces tumeurs monoclonales et monomorphes qui ne 
repondent pas a un essai raisonnable de reduction de l'immunosuppression, une 
therapeutique specifique plus agressive peut etre inevitable. En pratique, ces 
patients meurent souvent d'infections multiples. La mort des patients ayant des 
tumeurs monoclonales et polyclonales semble plutot en rapport avec un 
diagnostic tardif. Si 1'0n ajoute a cela Ie fait qu'il n'y a pas encore de marqueur 
pathologique absolu permettant de distinguer des tumeurs qui repondront ou pas a 
une reconstitution immunitaire chez un patient donne, et qu'il n'est pas encore 
evident de savoir a quel point la manipulation du systeme immunitaire peut inhiber 
la croissance tumoralc, la modulation de la therapeutique immunosuppressive 
parait necessaire des Ie debut du traitement. 
Nous avons demontre que les tumeurs monoclonales ou polyclonales peuvent 
etre soumises a des mecanismes de contrale a condition que la fonction immune 
puisse etre au moins partiellement restauree par une reduction de Ia therapeutique 
immunosuppressive. L'issue favorable dans un grand nombre de cas, apres 
modulation de I'immunosuppression a fait naitre l'idee de definir les parametres de 
I'hote et de la tumeur qui caracterisent dans ce systeme les mecanismes et les 
limitations du contrale immunitaire. 
* * 
* 
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Introduction 
The concept of immune surveillance, proposed almost 80 years ago (1), and 
more recently reiterated by THOMAS (2) and BURNET (3, 4) states that the principal 
defense mechanisms against the development of neoplasia consist of certain 
homeostatic processes of the immune system. There now exists considerable 
opinion that this concept can no longer be sustained in its original form (5, 6). 
Nevertheless, strong support for a specialized or restricted form of immune 
surveillance exists in the association of both spontaneous and induced states of 
immune deficiency with increascs in certain types of neoplasia (7-16). This 
relationship is nowhere being better exhibited than in patients undergoing organ 
transplantation and subsequent immunosuppression (8, 9, 13, 15, 17, 18-21). 
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It is clear that transplant patients receiving any form of immunosuppressive 
therapy have a higher propensity for the development of certain categories of 
tumors (17), especially lymphoproliferative disorders and Kaposi's sarcoma, 
Striking evidence that modulation of the immune system can control the growth of 
such neoplasia is offered by reports of remission of Kaposi's sarcomas and 
reversibility of lymphoproliferative lesions following reduction or cessation of 
immunosuppressive therapy in transplant patients (9, 18,22-27), This chapter will 
deal primarily with our experience with and approach to post-transplant lympho-
proliferative disorders (PTLDs) under cyclosporine-steroid therapy. This group of 
patients represents the largest single institutional series reported to date. Similarly, 
Kaposi's sarcoma occurring after renal transplantation in our patient population 
will also be presented. 
Definition of post-transplant Iymphoproliferative disorders 
This group of disorders represents a collection of abnormal lymphoid prolifera-
tions occurring in transplant recipients, usually in association with active infection 
by the Epstein-Barr virus (EBV) (18, 28, 29). Histologically, the lesions are 
characterized by polymorphous to monomorphous proliferations of lymphoid cells. 
In polymorphous forms all stages of lymphocyte transformation may be re-
presented. Monomorphous forms are indistinguishable from non-Hodgkin's lym-
phoma occurring in non-immunosuppressed individuals. 
Precision in correlating histologic appearance and clinical behavior is compli-
cated by the fact that some monoclonal tumors appear amenable to conservative 
intervention, whereas some polyclonal tumors may pursue a fulminant course 
leading to the death of the patient. 
In light of these nosologic difficulties we employ the term PTLD in a generic 
sense to apply to any atypical, invasive and diffuse lymphoproliferation occurring 
in immunosuppressed transplant recipients. The adjective polymorphous or 
monomorphous is added based on the particular histologic appearance. The 
proliferation is also categorized as polyclonal or monoclonal based on the results of 
immunophenotypic or immunogenotypic assays. The presence or absence of EBV 
is determined as well. Whereas EBV is almost always found, we would include as 
PTLD any lesion that meets the above histologic criteria and in which EBV cannot 
be isolated, 
We have, on occasion, also used the term PTLD to apply to non-invasive, usually 
nodal-based, diffuse lymphoproliferations. These lesions, also associated with 
EBV, usually have a predominant plasmacytoid appearance and may be associated 
with retention of underlying architecture. We qualify such lesions as reactive 
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processes. They may occur alone or may be associated with more advanced and 
invasive lesions elsewhere. In order for this group of lesions to receive a final 
designation as PTLD. it is necessary that evidence of EBV be found. 
Epstein-Barr virus: General considerations 
Existing evidence clearly indicts the Epstein-Barr virus as a major co-factor in 
the pathogenesis of PTLDs (16, 18.20,28.29). The demonstration of such a direct 
relationship has allowed a better undcrstanding of the interaction between tumor 
pathophysiology and the immune system. and of more immediate importance. has 
given insight into a more rational and effective form of therapy for this disorder. 
EBV is a double-stranded DNA organism of the Herpes virus family. In man, 
EBV infects B-Iymphocytes and is the causative agent of infectious mononucleosis. 
It attaches to the cell via the C3d receptor (30) and. in vitro. penetrates the cell 
membrane within 12 hours (31). Its life cycle follows four stages: latent, then early, 
middle and late replicative. All latently infected cells contain the Epstein-Barr 
nuclear antigens (EBNAs). of which several types arc known. Concurrently, thc 
lymphocyte detcrmined mcmbrane antigen (LYDMA) is produced. Early antigens 
(EAs) are produced during the early replication phase and are necessary for DNA 
synthesis. which occurs during the middle replicative phase. Additional membrane 
antigens and viral capsid antigens (YCAs) are formed during the late replicative 
phase. The replicative activity is not only confined to the virus. but by analogy 
extends to the host lymphocyte as well. In vivo. 5-2()'X, of the B-Iymphocytes are 
EBN A-positive during the first week of infectious mononucleosis (31). These cells 
resemblc plasma cells and produce immunoglobulins (32. 33). By the second week 
of this condition, <2'Yo of the circulating B-cells are EBNA-positive and no longer 
show plasmacytic differentiation. The early host response to infection includes NK 
cell activity and interferon production (14, 34). The early T-Iymphocyte response is 
believed to offer cytotoxic activity in a non-HLA restricted manner, but this is soon 
surpassed by the emergence of a strong T-cytotoxic/suppressor population. These 
latter cells are directed against LYDMA (31) and are also thought to playa role in 
suppressing the maturation of B-cells into plasma cells. The T-c/s cells account for 
the atypical lymphocytosis observed during the disease and by their cytotoxic 
actions liherate EBNA from the infected cells. Anti-EBNA antihodies are 
characteristically identifiable in the serum 30 to 50 days after disease onset and 
normally persist for life. Although the infection and B-cell proliferation are 
eventually brought under control by the host's immune mechanisms. the virus 
remains indefinitely in a latent form. Recurrence of the lytic cycle is usually 
prevented by specific host memory T-Iymphocytes. 
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Patient popnlation 
The incidence of PTLDs following the transplantation of kidneys, livers, hearts, 
heart-lungs and pancrcas, and developing under cyclosporinc (CsA)-steroid 
therapy at the University of Pittsburgh Health Ccnter betwcen January 1981 and 
August 31, 1986 is listed in Table 1 according to year and organ type. Tumors prior 
to this date occurred while the transplant tcam was based at the Univcrsity of 
Colorado and are included as part of this series. 
A total of 36 (approximatcly 1.7%) recipients of various organs were identified 
as having developed lymphoproliferative disorders from 1 to 160 months following 
organ transplantation. The salient clinical features are described in Tables 2, 3 and 
4 for kidney, livcr, and heart or heart-lung recipients, respectively. The incidence 
of PTLD varied somewhat with the kind of transplant, bcing 1 (Yo for kidney, and 
2.2% and 4.6% for liver and heart and heart-lung transplants, respectively. 
The patients ranged in age from 1 to 62 years (mean 22 years) at the time of 
transplantation. Twenty of the patients were adults and 16 were pediatric patients. 
There was a male-female ratio of 2.6: 1. The tissue matching for donors and 
recipients was completely random for the non-renal transplants and nearly so for 
the renal transplants. 
Table 1. Frequency of post-transplant lymphoproliferative disorders (PTLD) at the University of 
Pittsburgh Health Center. 
-
According to veal' Numher of all organs Numher of PTLD 
transplanted 
YCi/r 
1980 2 
1<g~1 148 1 
1982 224 5 
19~P 303 10 
1984 438 4 
1985 526 8 
I <Jf:6 (8/31) 522 6 
---
Total 2161 36 
According to organ Iype Tolal number of tral1splants Number of PTLD 
-
Organ 
Kidney 975 10 
Liver 855 19 
Heart 272 5 
Heart-lung 43 2 
Pancreas 16 0 
Total 2161 36 
-
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Immunosuppressive therapy 
The mainstay of immunosuppressive therapy for almost all patients was 
cyclosporine (CsA) and steroids. For kidney transplants who developed PTLDs, 
immunosuppression was with CsA and prednisone as previously described (18). 
Eleven of the 20 liver recipients who developed PTLDs were treated similarly. Six 
liver recipients also received monoclonal antibody (OKT3) and 1 patient received 
Table 2. Kidnev recipients with lymphoproliferative disorders. 
Case Sex Age (yr) Date of Time (Mo) Organs Clinical Surgery 
at Tx fx of onset in\'olved presentation 
ofPTLD 
after Tx 
I F 25 Jan. 31, 6 Ileum Perforation Small bowel 
1980 of ileum resection 
2 M 28 Fcb.19, 3.5 Liver, spleen, Fever None 
1980 heart, 
retroperitoneal 
lymph nodes 
(necropsy findings) 
3 M 20 April 15, 6 lIeum. small Perforation Small bowel 
1981 bowel. of ileum resection 
mesentery 
4 M 52 May 4, 3.5 Submandibular Fever. Local resection 
1982 gland adenopathy 
5 M 56 Feb.lO, 6 Prostate, Prostatic 
1982 ileum, mesentery obstruction 
and perforation 
of ileum 
6 M 30 July 10, 4 6 sites in Perforation 
1982 small bowel of ileum 
7 M 16 Dec. 12, 3/"2 Multiple sites Perforation 
1982 in small bowel of ileum 
-
g F 62 March 14, 4Y, Stomach GI bleeding 
1983 
\I M I:" Jan.6, (, ·j(lDsils. nasopharynx Sore throat 
1985 
III M 11 May 3. 13 Adenoid hyper- Upper rcspira-
1985 plasia tory infection 
Tx = transplantation; CsA = cyclosporinc; TOO = thoracic duct drainage; Pred = prednisone, 
Aza = a7athioprine; ALG = antilymphocyte glohulin; ATG = antithymocyte globulin. 
TURPand 
small howe I 
resection 
Small bowel 
resection 
--
Small bowel 
resection 
Biopsy 
TbnsillcctotTIy 
Adenoidectomy 
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azathioprine additionally. The remaining 2 liver recipients had their transplants in 
1972 and 1977 under azathioprine and prednisone. The latter patient was converted 
to esA and prednisone in 1981. In addition to esA-prednisone therapy, 1 heart-
lung patient received azathioprine, and 3 heart transplant patients were also 
treated with anti-thymocyte globulin (ATG). One heart-lung patient received 
quadruple therapy with ATG, azathioprine, esA and prednisone (Table 4). 
Contempo· Original Change in Acyclovir Other anti- Fate of Graft 
f3I1eOUS immuno- immunosuppression tumor treatment patient function 
infection suppression CsA Pred 
(mg/kg/day) (mg/day) 
None TOO. 16-6 10-10 No None Alive, Retained 
CsA, Pred tumor-free to date 
Pneumoeystis CsA, Pred 14-14 25-20 No None Died June 8, Functioned 
carinii 1980 until death 
I 
None CsA, Pred 18-9 20-10 No None Alive, Retained 
tumor-free to date 
Herpes CsA, Pred 11-2 20-15 No 5400 rad cervical Alive, Retained 
simplex irradiation tumor-free to date 
None CsA, Pred 8-2 15-15 No Doxorubicin, Alive, Rejected 
cyclophos- tumor-free 1 yr later, 
phamide, ReTx lost 
vincristine: can- to hyperacute 
celled mid-course rejection 
-
Herpes CsA. Pred 10-0 15-15 No Doxorubicin, Alive, Rejected 
simplex eyclophos- tumor-free in 2 wk, ReTx 
phamide, retained 
vincristine to date 
None CsA, Prcd 8-0 15-15 Yes None Alive, Rejected 
tumor-free in 1 wk, being 
evaluated for 
ReTx 
Herpes CsA, Pred 8-1 15-15 No None Alive, Retained 
simplex tumor-free to date 
None CsA, Pred 6-0 17.5-15 No None Alive, Retained 
tumor-free to date 
None CsA, Pred 5.5-3.6 5-5 No None Alive, Retained 
tumor-free to date 
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Clinical presentation 
Typically, the onset of the disease took place fairly rapidly after transplantation, 
with 19 of the 36 cases occurring in less than 6 months, and 31 of the 36 cases 
occurring within the first year. The interval from transplant to diagnosis of PTLD 
was as short as 1 month or as long as 14 years. In our series. there was one instance 
of PTLD occurring 2 years after conversion from azathioprine to CsA therapy and 
1 example of a case occurring 2 years after transplant in a patient who had received 
CsA-prednisone therapy from the time of transplant. The only case with onset 
Table 3. Liver recipients with lymphoproliferative disorders. 
Ca,e Sex Age (yr) Date Time (mu) Organs Clinical Surgery 
atTx ofTx of onset involved presentation 
ofPTLD 
after Tx 
) F l.5 Feb. 20. 160 Generalized (lymph Fever, jaundice, Lymph node bx. 
1<)72 nodes, tonsils_ mild chronic re- tonsillectom} 
lungs, liver, CNS. jection, tonsillitis 
uterus, ovaries) 
2. F 13 Aug.31. 68 Cervical nodes, Renal mass Resection 
1<)77 right kidney 
3. M 17 May 9. 6 Small bowel Fever. small Small bowel 
1982 (multiple ) bowel obstruction resection 
4. F 8 Nov. I, 39 Diffuse Fever, weight Lymph node ox 
1982 retroperitoneal loss, anorexia 
(lymph nodes. kid-
neys, adrenal), 
heart, brain, bone 
marrow OJ tract 
5. M 20 Dec.!. 8.5 Cervical nodes, Fever, Tonsillar bx 
1982 tonsils tonsillitis 
6. F 21 Mar.20. 6.5 Ileum and colon Fever. vague in- Small howel 
1983 (multiple) testinal symptoms resection 
7. F 26 Scpo 1. 4 Diffuse lymph Multi-organ Biopsy 
1983 nodes. GI tract, failure 
pancreas 
R. M 23 Oct. 30, 2 Diffuse lymph Disseminated Biopsy 
I'lR3 nodes. spleen sepsis, severe re-
jection with liver 
mycosis 
PCP = Pneumocystis carinii pneumonia, CMV = cytomegalovirus; CsA = cyclosporine, Pred = prednisone, 
AZA = azathioprine; hili bilirubin; LFTs = liver function tests, Tx = transplant. 
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beyond this time period occurred 160 months after liver transplantation in a patient 
whose sole immunosuppression had been azathioprine and prednisone. This last 
patient was from an era in which lymphoproliferative complications were common, 
but usually identified as reticulum cell sarcomas (8, 9). HANTO et al. (20) have 
reported the largest series of these lesions under azathioprine-prednisone therapy 
with or without ALG. 
The presenting symptoms can be extremely variable, and sometimes the patient 
may be completely asymptomatic. Therefore, a high index of suspicion must be 
maintained for early diagnosis. The presentation may include any of the following: 
Contempo- Original Change in AcycloviI Other antitumor Fate Graft 
raneous immuno- immunosuppression treatment of patient function 
infection suppression CsA Prcd 
(mg/kg/d) (mg/d) 
Aspiration Aza, Prcd, 10-0 10-5 No None Died of resp. Functioned 
pneumonia then CsA, arrest aftcr until death 
Pred after tonsillectomy 
mid 1984 
---
None Aza, Pred. R-2 15-10 No None Died after Failed slowly; 
ALG, then ReTx; had ReTx 
CsA, Pred microscopic 
from tumor 
Sep.1981 
None esA. Pred 20-3 25-10 No None Alive, Retained 
tumor-free to date 
Generalized esA. Pred 11-0 5-5 Yes Vincristine Died of Functioned 
aspergillosis daunomycin multiple until death 
prednisone organ failure 
None CsA, Pred 6-6 10-10 No None Died 01 Functioned 
airway oh- until death 
struction after 
ENT 
examination 
Cholangitis, CsA, Pred 13-5 10-7.5 No None Alive. Retained 
fungal tumor-free to date 
pneumonia 
PCP. CsA. Pred 1:1-0 15-5 No None Died of Functioned 
candidiasis pneumonia until death 
C'vIV, esA, Pred 1.2 12.5 No None Died of sepsis Functioned 
Theudomonas (PTLD found until death 
aeruginosa at autopsy) 
sepsis 
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lymphadenopathy, fever, weight loss, abdominal pain, tonsillitis, night sweats, 
upper respiratory infection and diarrhea. The patient may present with swollen 
tonsils of such magnitude that emergency tracheotomy is required. In several cases 
PTLDs gave rise to an acute abdomen, gastrointestinal perforation, obstruction or 
hemorrhage (Tables 2-4). Some patients presented with a syndrome indistinguish-
Table 3 (continued). 
Case Sex Age (yr) Date Time (mo) Organs Clinical Surgery 
atTx ofTx of onset involved presentation 
ofPTLD 
after Tx 
9. M 4 Jan.14, 24.5 Terminal ileum Abdominal pain, Hemicolectomy 
19R4 lymph nodes, small lymphadenopathy. then excision of 
bowel mesentery, large epigastric mass 3 months 
transverse mass, hyper- later 
mesocolon calcemia 
10. M 32 Apr. 2, 6 Diffuse lymph Fever, anorexia Lymph node hx 
1984 nodes 
11. F 2.5 May 10, 3 Cervical nodes, Fever, upper air- Tracheostomy, 
19S4 tonsils way obstruction lymph node hx 
tonsillectomy 
12. M 7 Aug.6, 7.5 Diffuse lymph Fever tonsillitis Lymph node bx 
1984 nodes, tonsils tonsillectomy 
13. M 3 Aug. 7, . 11 Lymph nodes (ccr- Fever, anorexia Lymph node 
19S4 vical. retro- vague ahdominal bx 
peritoneal). tonsils pain 
14. M 1.5 May 18, ]() Adcnoids Upper respiratory Adenoidectomy 
1985 infection, middle 
ear infection 
IS. F 3.5 Aug. 22, 4 Diffuse lymph PCP Biopsy 
1985 nodes, spleen 
16. F 11.5 Sep.19. 2 Diffuse lymph Multi-organ Biopsy 
19R5 nodes. liver, Gr failure 
tract. kidneys 
17. M :1.5 Dec. 17, U Diffuse lymph Fever, diarrhea, Biopsy 
1985 nodes elevated bili and 
LVf's 
1~K M 43 Feb. 25, 5 Lungs PCP with non- Open lung bx 
1986 resolving X-ray 
findings 
19. M 2.5 Apr. 10. 2 Adenoids Hoarseness Adenoidectomy 
1986 
PCP = Pneumocystis carinii pneumonia. CMV = cytomegalovirus; CsA = cyc1osporine, Pred = prednisone, 
AZA azathioprine; bili = bilirubin; LFTs = liver function tests, Tx = transplant. 
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able from infectious mononucleosis, consisting of lymphadenopathy and fever. 
Some of the more unusual methods of presentation included lung lesions, a renal 
mass, prostatic obstruction, disseminated sepsis and multi-organ failure, The 
presentation at times mimicked rejection. In those cases, the presence of an 
atypical lymphoblastic infiltrate on biopsy was often the first indicator of a PTLD. 
Con tempo· Original Change in Acyclovir Other antitumor Fate Graft 
raneous immuno- immunosuppression treatment of patient function 
infection suppression CsA Pred 
(mg/kg/d) (mg/d) 
---
None CsA. Pred. 5.5-0 5-0 No None Alive; tumor Retained 
OKT3 regressed. to date 
then recurred 
in the small 
bowel and 
\vas resected 
Esophagitis CsA. Pred 7.5-3.3 17.5-10 Yes Radiation Alive. Rejected; 
(herpes? CMY'I tumor·free ReTx 
None CsA. Pred 15.5-7.8 10-5 Yes None Alive. Retained 
tumor·free to date 
None CsA. Pred 22-11 15-10 Yes None Alive Retained 
tumor-free to date 
-
None CsA, Pred 19-12 7.5-5 No None Alive. Retained 
tumor-free to date 
None CsA, Pred, 35-12 7.5-5 No None Alive, Retained 
OKT3 tumor-free to date 
PCP CsA, Pred, 13.3 to No None Diedofsep- Functioned 
OKT3, Aza sis, autopsy until death 
finding 
CMV, CsA, Pred, 23 10 No None Died of multi· Functioned 
Candidiasis OKT3 organ failure; until death 
( autopsy 
finding) 
None CsA, Pred. 30-5-U to-5-0 Yes None Died of multi· Failed 
OKT3 
I 
organ failure 
PCP.CMY . CsA. Pred. 5.5 .. 0 7.5-5 No None Alive, Retained 
OKT3 free of tumor tod,,(e 
None CsA. Pled, 50-30 10-5 No None Alive. Retained 
OKT3 tumor-free to date 
Table 4. Heart and heart/lung recipients with lymphoproliferative disorders. 
Case Sex Age lyr) Date Time (Mo) Organs Clinical Surgery 
at Tx ofTx of onset involved presentation 
ofPTLV 
after Tx 
I M 51 Sept. 27. n.5 Lung:. adrenal Fever Biops} 
1982 
2 M 22 Nov.l. 1i.5 Cervical nodes. Ccrvica I mass Biops) 
1981 pharynx,lun!!s 
.l 1\1 44 Jan.20. .l Inguinal nodes Inguinal mass Biops) 
1983 
"4 M 20 Jan. 21, 4 Cervical nodes, Cervical mass Biopsv 
]'183 ileum, other 
lymph nodes 
','i M 22 May 2S. 2 Tonsils Tonsillitis Tonsil-
1983 lectomy 
(, M 30 Oct. 22. 3 Cervil'al nodes Cervical Biopsy 
1984 adenopathy 
-
7 M S6 Jan. 19. 3 Cervical nodes Fever. cervical Biopsy 
1985 adenopathy 
." Cases 4 and 5: heart/lung recipients. 
PCP = Pneumocyslis carinii pneumonia, CMV = cytomegalovirus; AZA = azathioprine, ATG = anti thymocyte 
globulin. 
The organs involved with PTLD in each patient arc summarized in Tables 2,3, 
and 4; the head and neck areas and the gastrointestinal tract were the most 
commonly involved regions in our series. 
A fulminant course is uncommon, tcnds to involve multiple organs and usually 
leads to death within such a short period of time that stopping immunosuppression 
may be too late. In 3 patients the diagnosis was not made until necropsy. 
Infectious disease studies 
The results of studies assessing infection with EBV in PTLD patients are listed 
in Table 5. Serological evidence of active infection with EBV around the time of 
PTLD was found in 33 of 36 patients (92%). Although Epstein-Barr virus nuclear 
antigen (EBNA) was demonstrated in only 15 of 24 tumor specimens in which it 
Contempo- Original Change in Acylovir Other antitumor Fate Graft 
raneous immuno- immunosuppression treatment of patient function 
infection suppression CsA Prednisone 
(mg/kg/d) (mg/d) 
CMY CsA. Pred S~S OM~OM Yes None Died Functioned 
pneumonia April 13, until death 
1983. CMY 
pneumonia 
Pneumonia CsA. Aza. U~U OM~OM Yes Cyclophos- DiedOeL 27, Functioned 
Pred phamide, 1982, until death 
vincristine, paneyto-
procarbazine, penia, sepsis 
irradiation 
Gastroenteritis CsA.Pred, O1~1P PM~OR No None Died Oct. 6. ReTx 
AfG 1984 April19S4 
respiratory 
failure 
I 
tumor-free 
Systemic CsA.Aza. U~O OM~1R Yes None Died June 24, Functioned 
crypt()coccosis Pred 19R3. ileal until death 
('MY 
PCP 
PCP 
--
perforation 
CsA. Aza 1O~P Olg~Oll Yes None Died follow- Retained 
Pred. ATG ing re-Tx, until 
Dec. 18. 1984, Dec. 19R4 
tumor-free 
CsA. Pred. 6.6-3.3 OM~OM No None Alive, Retained 
ATG tumor-free to date 
CsA. Pred. RKU~O 20-20 No None Alive. Retained 
ATG tumor-free to date 
Table 5. Infection with Epstein-Barr virus. 
Kidney Liver Heart or Total cases 
heart-lung 
Serological evidence of 8110 18/19 717 33/36 
active EBV infection' 
~ Primary 5 13 4 22 
- Reactivation :; 5 3 II 
- None'"* 2 1 - 3 
Tissue EBNA 115 10/12 417 15/24 
EBV genome 3/4 2/3 4/4 9f11 
, Serum was obtained prior to or at transplantation and at least at monthly intervals after 
transplantation. Primary infection was defined as serologic conversion from a seronegative state for IgG 
against EBV virus capsid antigen (VCA) after transplantation to a seropositive state. Reactivation 
infection represented a four-fold or greater serological rise of IgG anti-VCA. Primary and reactivation 
infections occurred before or around the time of tissue diagnosis of a lymphoproliferative lesion, 
*-' Evidence of old infection, but reactivation not clearly demonstrated. 
EBNA: EBV nuclear antigen, determined by immunofluorescent staining on touch preparations and 
frozen tissue sections. 
EBV genomes were demonstrated in 9 of 11 tumors (including 6 negative tissue EBNA) which were 
examined with DNA hybridisation techniques by J. PAGANO (University of North Carolina), G, MILLER 
(Yale). or M. A. EpSTEIN (Bristol). 
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Fig. I. Low power photomicrograph of PTLD from case report 2 shows large areas of amorphous 
necrotic debris interdigitating with cellular areas (Hematoxylin and eosin). 
was tested for, 9 of 11 tumors examined by DNA hybridization studies contained 
EBV genomes . These 9 included 6 that had negative EBNA studies. It is also of 
note that there were twice as many primary as reactivation EBV infections. 
Other infections occurring just before, or at the time of diagnosis of PTLD are 
catalogued in Tables 2-4. A significant number of patients had severe contem-
poraneous infections, which in some cases were a major factor in their deaths. 
Fig. 2. A tonsillar lesion from case 1 shows the interface between viable and necrotic tissue . A large 
atypical CEil is seen in this area . Elsewhere the lesion 'had a polymorphous lymphoid appearance 
(H and E). 
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Eighteen of the 36 patients had no other infections, while another 4 had only 
Herpes simplex infection. 
Histopathology 
The characteristic histologic appearance of PTLD is that of a diffuse invasive 
lymphoproJiferation with varying degrees of cellular polymorphism, necrosis and 
plasmacytoid differentiation. 
Fig. 3. Minimally polymorphous PTLD which typeu as monoclonal by immunoglobulin gene rearrange-
ment analysis. Inset: Rare atypical cells found within the tumor (H and E). 
Fig. 4. Monomorphous noncleaved cell tumor found in an intrapulmonary location . Clonal analysis had 
nOl been performed on this consult biopsy from an outside institution. The patient is well withuut tumor 
Y months after diagnosis following a reduction of immunosuppression (H and E). 
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On low power, the necrosis may assume the form of interweaving swaths of 
infarction ("geographic" necrosis) (Fig. 1) separating areas of viable cells. The 
interface between necrotic and non-necrotic areas may show an exaggerated 
cellular pleomorphism due to the superimposition of inflammatory cells, moribund 
cells, and scattered large atypical cells characterized by prominent nucleoli, 
poly lobated nuclei and a moderate amount of cytoplasm ("atypical immunoblasts") 
(Fig. 2). These latter cells are considered by some to be harbingers of malignant 
transformation, but have also been described in uncomplicated infectious mono-
nucleosis (35). The frequent propinquity of these cells to necrotic foci suggests a 
response to a toxic microenvironment, but similar cells can also be seen removed 
from such areas (Fig. 3, see also Figs. 9, 10, 15). Thus, their nature remains 
enigmatic. We do not consider such cells to represent evidence of a true malignant 
lymphoma in this patient population. 
The polymorphism of the predominant population of cells in PTLDs reflects the 
various stages of lymphocyte transformation. In general, there is a tendency for the 
terminal stages of B-cell differentiation to be well represented. Thus, many of the 
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Fig. 5. Post-operative course of a 2V,-year-old female livCf recipient who developed PTLD resulting in 
acute upper airway obstruction and requiring tracheostomy, tonsillectomy and reduction in immuno-
suppression. 
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Fig. 6. Re presentative radiog raph of upper airway obstruction in a PTLD patient. 23-year-olc..i male 
9 mo nths after carc..ii;Jc tra nsplantation prese ntcc..i with upper airway obstruction. Rac..iiograph demon-
strates a large soft ti ssue mass in the nasopharynx . 
Fig. 7. Diffuse plasm<lcytoid I'rolikr,ltion frolll inguinal lymph node of case l. This was associated with 
retentio n of underlying architecture and WaS judgcc..i a reactive process (H a nd E). 
588 L. Makowka et aL 
lesions show varying degrees of plasmacytoid or frank plasmacytic differentiation 
(see Figs. 7, 16). Although this may be seen in the context of diffuse proliferation 
and necrosis, early. cases may show a nodal-based, benign appearing diffuse 
plasmacytic hyperplasia. We have also seen this appearance concurrently with the 
presentation of a more typical noncontiguous PTLD. 
Other cells constituting the polymorphous infiltrate range from small lympho-
cytes through immunoblasts. Occasionally a dimorphic appearance is seen, which 
suggests an infiltrate of reactive lymphocytes, possibly T-cells, into a proliferating 
population. Given the importance of these lesions to the immune surveillance 
theory and/or immune control mechanism, the paucity of information regarding 
infiltrating cell types is perhaps surprising. Such analysis is planned at our 
institution and may alter our classification of these lesions in the future. 
Many PTLDs are composed of a clearly monomorphous cell population 
(Fig. 4). The cells in these instances are either small or large noncleaved 
lymphocytes with essentially no evidence of plasmacytoid differentiation. Necrosis 
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Fig. 8. Post-operative course of a 21-year-old female liver recipient who developed diffuse small bowel 
and colonic PTLD with GI bleeding requiring resection and reduction in immunosuppression for 
resolution. 
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Fig. 9 . Region of il eoceca l valve and ascend ing colon from case 2 shows multiple ulceronodular tumor 
masses as viewed from thc mucosa l aspect of the bowel. 
may be present or absent; single-cell necrosis may be the predominant type seen. A 
monomorphic pattern represents a significant departure from the usual PTLD and 
may be the manifestation of a lesion further advanced along the pathway of tumor 
progression. 
Clonal designation of the tumors is an integral component of pathologic analysis 
(36-39). In lesions showing strong plasmacytoid fea tures, immunocytochemical 
Fig . Ill. Rcrresentativt; hi stologic sec ti o n fro m onc o f the tumors in caSt; 2 uell10 nstrates a 
polymorphous infiltrate with a la rge atypical cell nea r the center of the photugraph (H auu E) . 
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staining for immunoglobulin light chains in paraffin-embedded material may 
provide enough information for presumptive clonal analysis (sec Figs. 16, 17,20, 
21). In many cases this approach is unsatisfactory and immunophenotypic analysis 
requires the use of frozen section immunohistochemistry (sec Figs. 11, 12), flow 
cytometry (sec Fig. 27) or a combination of the two. We currently favor the use of 
immunoglobu 'lin gene remrangement analysis by DNA restriction fragment length 
Fig. 11. Immunofluorescence preparation of frozen tumor secti()n from case 2 shows positivity directed 
against kappa light chains. 
Fig . 12. Preparation simila r to ci~K 11 showing negative s taining whe n primary antibody is directed 
ag;lin,t human lambda light chains. 
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polymorphism and have verified the clonal status in many of these tumors by this 
technique (manuscripts in preparation). 
In reviewing our cases it has become apparent that histologically monomor-
phous tumors are also monoclonal. Histologically polymorphous tumors may be 
either polyclonal or monoclonal. This latter finding underscores the limitation of 
routine histology in the analysis of these tumors. Indeed, in practice it is difficult to 
define the lower limit of polymorphism allowable before classifying a tumor as 
monomorphous. Clearly, more refined pathologic dissection of PTLDs is required 
before a final classification can be agreed upon. 
Our current practice is to use the term PTLD as a generic diagnosis for a 
histologically verified diffuse lymphoproliferation occurring in a transplant recip-
ient. The diagnosis is corroborated by identification of EBV within the lesion. 
The histologic diagnosis is further specified by the adjectives polymorphous or 
monomorphous as an estimate of the diversity of lymphocytes within the lesion. 
Likcwise, the clonal designation of polyclonal or monoclonal is given based on 
immunophenotypic studies. This is then substantiated by immunogenotypic 
analysis, at which time the possibility of an oligoclonal tumor may also be 
revealed. 
The relationship of histologic appearance to the pathogenesis of this disorder is 
considered in the discussion. 
Response to therapy, patient survival and graft function 
Kidney transplant recipients (Table 2): Nine out of the 10 kidney recipients with 
PTLD are alive. Of the 9, the tumors were monoclonal in 4, polyclonal alone in 2, 
and of unknown clonality in 3. Two of the patients with monoclonal tumors also 
had separate polyclonal tumors. The tenth patient had a monoclonal tumor that 
was not diagnosed until autopsy. Death in this patient was due to Pneumocystis 
carinii pneumonia and not tumor. In all surviving patients the diagnosis was made 
from biopsy specimens. Eight of the 9 survivors had in common the reduction or 
discontinuance of immunosuppression. Surgical intervention consisted of either 
resection or biopsy of visible tumor. Only 1 of the surviving patients was treated 
with acyclovir. Two patients were treated with multiple chemotherapeutic agents 
and another had 5400 rad cervical irradiation. In retrospect, this treatment was 
unnecessary and probably undesirable. 
Five of the survivors had operations to relieve the complications of bowel 
involvement caused by PTLD. All had reduction of immunosuppression, and there 
has been no evidence of residual tumor. The renal grafts in 3 of the 9 survivors 
were rejected 1 week to 1 year after the reduction of immunosuppression. The 
kidneys of the other 6 recipients are functioning well. 
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Liver transplant recipients (Table 3): Ten of the 19 liver recipients with PTLD 
are alive. Three of the survivors had monoclonal tumors, 5 had polyclonal tumors, 
and in 2 patients the clonality is as yet undetermined. Of the 9 patients who did not 
survive, the diagnosis of PTLD was made at autopsy in four. One of these 4 had a 
polyclonal proliferation; clonality was indeterminate in the other 3. Five other 
patients who died received an antemortem diagnosis of PTLD. In this group, 1 case 
was monoclonal, 2 were polyclonal and 2 were of indeterminate clonality. 
All 10 survivors had a reduction in immunosuppression, while 4 patients who 
had no adjustment in immunosuppression died. Two of 5 patients who received 
acyclovir died. One patient received radiation therapy and is alive, while another 
who received combination chemotherapy died of multiple organ failure. Three 
patients who underwent bowel resections are thought to be tumor-free. Two 
patients lost their grafts due to rejection after their immunosuppression was 
lowered, and both were successfully retransplanted. One patient has had several 
local recurrences of tumor over a 1 year period. He is currently doing well with no 
clinical evidence of tumor. 
Heart and heart-lung recipients (Table 4): Two of the 7 heart or heart-lung 
recipients with PTLD are alive. These 2 patients had a significant reduction in 
immunosuppression. In 1 case the tumor was polyclonal, in the other, monoclonal. 
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Fig. 13. Post-operative course of a 16-year-old male kidney transplant recipient who developed diffuse 
small bowel PTLD and perforation requiring emergent resection and cessation of cyclosporine therapy. 
resulting in complete resolution of disease but loss of the graft due to rejection. 
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Fig . 14. Reprcsc:ntative pre-operative radiographic appearance of a small bowel PTLD in a 17-year-old 
male 5 months post liver transplant. Small bowel S.ludy shows submucosal masses with obstructive 
dilatation of the small bowel. 
Neither patient received acyclovir and neither had problems with allograft 
rejection. Three other patients in whom the immunosuppression was reduced did 
not survive . One of these patients (case 4) died of abdominal sepsis after delayed 
diagnosis of a perforated PTLD of the ileum. This patient had already had a 
previous diagnosis of PTLD made on biopsy of enlarged cervical nodes. However, 
no response of the monoclonal PTLD to a reduction of immunosuppression was 
documentable in this patient. The 2 other patients died at 1 year and 18 months, 
respectively, following diagnosis of PTLD. In both cases the polyclonal tumors 
resolved following reduced immunosuppression and had not recurred. Both 
patients died of other, unrelated causes. A heart recipient who received 
chemotherapy, regional irradiation and acyclovir instead of reduction of 
immunosuppression died of widespre~d infection . The chemotherapy caused 
profound bone marrow depression. Residual foci of PTLD were found at autopsy. 
Case histories 
The following case histories are representative of the clinical presentation, 
diagnostic problems, pathologic considerations and management approach charac-
teristic of the series of patients with PTLD at the University of Pittsburgh Health 
Center. 
594 L. Makowka et al. 
Fig. 15. R e presentati ve view of tumor frolll case 3. Polymorphic infiltrate with large atypical cell is 
apparent. Higher powe r showed plasmacytoid differentiation (H and E). 
Case 1: A 2i2-year-old female with biliary atresia and a history of a failed Kasai 
procedure and revision, underwent uneventful orthotopic liver transplantation . 
Her post-operative course is depicted in Fig. 5. Her recovery was prolonged 
because of a severe ischemic injury to the donor liver. This eventually resolved 
with excellent final function on discharge, 6 weeks later. Two months after 
discharge, shc developed a fever of unknown origin, anorexia, malaise, cervical 
and inguinal lymphadenopathy, and tonsill<ir enlargement of sLlch a magnitude that 
Fig. 16. Immunope roxidase stain for intracy toplasmic lambda light chain in case 3. Plasmacytoid 
features facilitate inte rpretation. Note positive staining of imlllunobl"sts (Avidin-biotin complex 
illlmunoperoxidasc , diaminobcnzidine development). 
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Fig . 17. Similar preparation as in Fig. 16 using antibody stain directed against kappa light chain. No 
intracytoplasmic staining is evident. 
upper respiratory impairment developed (Fig. 6 represents a radiographic illustra-
tion of a similar finding in another patient in our series) . This required emergency 
tracheotomy. At the same time, a tonsillectomy and an inguinal lymph node biopsy 
were performed (Fig.2 represents the histology taken from the tonsil and Fig. 7 
from the inguinal node). The tonsil showed confluent areas of necrosis (d. Fig. I) 
with a florid , diffuse, polymorphous proliferation of lymphocytes, plasmacytes, 
plasmacytoid cells, immunoblasts and Reed-Sternberg-like cells. A lesser degree of 
plasmacytic proliferation was observed in the lymph node, with good retention of 
underlying architecture. The process was judged to be polyclonal on the basis of 
immunoperoxidase staining for immunoglobulin light chains. 
The patient's im munosuppressive therapy was reduced, cyclosporine from 15.5 
to 7.75 mg/kg/day and prednisone from 10 to 5 mg/day (Fig. 5), and she received a 
full course of intravenous acyclovir. The patient recovered promptly, and she is 
currently well 2 years later, with normal hepatic function and receiving relatively 
reduced immunosuppression. 
Case 2: A 21-year-old female underwent emergency orthotopic Ii ver transplanta-
tion for fulminant hepatic failure following right hepatectomy for fibrolamcllar 
hepatoma. Her original liver disease was congenital tyrosinemia and macronodular 
cirrhosis. At the time of liver transplantation, it was found that her portal vein had 
been ligated at the time of partial hepatectomy. This necessitated the use of a 
venous graft for portal vein reconstruction. Her post-operative course was quite 
uneventful and she was discharged with norma'i hepatic function (Fig . 8). She was 
re-admitted 6 months later with elevation of liver enzymes. During her work-up an 
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Fig. IS. Low power photomicrograph of bowel w~1f from case :\ showing resolving lesion. Notice 
flattened regenerating epithelium covering upper portion of bowel wall. The ex tent of remaining 
infiltrating cells is estimable at this power. Notice involvement of submucosa , muscularis propria and 
serosal aspect (H and E) . 
Fig. 19. Close-up of muscularis propria shown in Fig. 18. Infiltrating cells <Ire small mature plasma cells 
(H and E) . 
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Fig . 20. Immunoperoxidase stain of intracytoplasmic lambda light chains in plasma cells infiltrating 
muscularis propria in patient 3 (d. Figs. 18 , 19) . Note cri sp granular intracytoplasmic staining of the 
cells in ques tion (Avidin-biotin complex immunoperoxidase, diaminobenzidine development). 
Fig. 21. Immunope roxidase preparation similar to Fig. 20 with antibody directed against ka ppa light 
chain. No staining of plasma cells is evident. 
ERCP was pe rformed, which demonstrated a stricture of the common bile duct. 
The patient developed severe pancreatitis and (ldult respiratory distress syndrome 
as a complication of the ERCP. The patient's condition was further complicated by 
gastrointestinal hemorrh(lge from an undetermined site. As soon as she was st(lbk 
enough, she was taken to the operating room for explor(ltion, with the intention of 
revising her biliary tree. She was found to have multiple tumors involving the 
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terminal ileum, ascending and transverse colon (Fig. 9). An extended right 
hemicolectomy was performed, as well as a ROllx-en-y cholcdochojejunostomy 
revision of the bile duct. A total of 27 cm of terminal small bowel and 30 cm of 
adjacent colon was resected. This portion of bowel contained a total of 16 separate 
tumors, most of which had yellow-grcen, necrotic appearing bases (Fig. 9). Several 
tumors grossly involved the entire thickness of bowel wall. Microscopically a focus 
of extra-intestinal tumor extension was secn. Eight regional lymph nodes were 
negative for tumor. The intestinal tumors were extensively necrotic (cf. Fig. 1) and 
contained a gcnerally polymorphous population of lymphoid cells and occasional 
large atypic<.ll cells (Fig. 10). At least one of the tumors was judged to be 
monoclonal Oil thc basis of strongly positive immullofluorescence staining for 
kappa light chain (Fig. 11) and concomitant negative staining for lambda light chain 
(Fig. 12). 
Her post-operative management consisted of a significant reduction of 
immunosuppression to approximately one-third previous levels, CsA from 13 to 
5 mglkglday and prednisone from 10 to 7.5 mg/day (ef. Fig. 8). Her recovery was 
Fig. 22. Follow-up small bowel study in case :1 at approximately 3 months after allograft nephrectomy 
demonstrating no evidence whatsoever of GI trilct involvement. 
Control of PTLDs and Kapos i's Sarcoma by Modu la tion of lmmunosuppression 599 
I.IG/DL 
8 
I.U. 
1000 r 
750 ~ 500 
250 ....n ..--. Ian ~ .zJ 
I.IG/KG/D.W 
:~ rrrBR1ltrJ 
B.M. 
RT HEMICOLX 
LYMPHOPROLI 
-
- f"'1 
I.IG/OAY • PREDNISONE 
.. f~~ • STEROID CYCLE 
OM t~ •• a. 
2 3 6 7 115 116 
WEEKS 
1/14/84 
BILIRUBIN 
EPIGAST MASS 
LYMPHOPROLIF 
• SGOT 
IZl SGPT 
NG/UL 
D CYA DOSE .1 1500 
- LEVEL 1000 
500 
HYPERCA++ 
134-5 142-5 
Fig . 2.'\. Post-operative course of a 4-year-old mal e liver transplant n;cipicnt who presenll:d with 
terminal ileal PTLD, and then developed 2 Jarge epigastric recurrence. which e,lch re4uircd resection 
and cessation of illlmun os uppn:ss ion for control. 
Fig. 24 . Representat ive section of tUlllor from case 4. Monumorphous proliferation uf smu llnonclcavcd 
ce ll s are admi,xed with smal ler dark cells represen tin g examples of individual ce ll necrosis. Seve ral 
recurrences of this tumor showed an identical patLt:rn with no morphologic evidence of tumor ce ll 
mat ura tion . 
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Fig.25. Small bowel study to investigate the first appearance of recurrent PTLD in the epigastrium. 
]{.ldiogr<lph demonstrates displacement of small howel by large anterior epigastric mass (arrows), but 
with apparently no invasion of the small howcl mucosa. 
rapid, and she is alive and well with normal liver function approximately 3 years 
later. 
Case 3: This 16 year old male with Lawrence-Moon-Biedl syndrome underwent 
a cadaveric renal transplant for end-stage renal disease secondary to his primary 
disorder. His post-operative course was smooth and he was discharged in 4 weeks 
(Fig. 13). He presented 2 months later with severe diarrhea and guaiac positive 
stools. After being observed in the hospital for 3 days, the patient developed an 
acute abdomen secondary to a perforated hollow viscus. He was explored 
immediately and was found to have multiple tumors involving the ileum and the 
hepatic flexure of the colon, with 3 areas of obvious small bowel perforation. The 
gross appearance was similar to that described in Fig.9 for Case 2. (Fig. 14 
represents the pre-operative radiographic diagnosis and appearance of a small 
bowel PTLD in a different patient with similar findings). Segmental resections of 
the small bowel and colon with primary anastomoses were performed to remove 
only some of the tumors. Fig. 15 represents the histo logy of 1 of the primary 
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Iymphoproliferations in this patient. These were in general polymorphous with 
plasmacytoid differentiation. Immunoperoxidase staining of cytoplasmic lambda 
and kappa light chains is shown in Figs. 16 and 17 , respectively. Of 13 tumors so 
stained, 11 were monoclonal with lambda: kappa ratios of up to J 16: 1. Although 
the regional lymph nodes were not involved, all . of the tumors could not be 
removed. Post-operatively the patient's CsA dose was discontinued completely and 
his prednisone was maintained at 15 mg/day. He made a surprisingly smooth 
recovery, except for repeated episodes of lower gastrointestinal tract bleeding and 
the rapid developme nt of intractable rejection which required allograft nephrec-
tomy approximately 5 weeks after the initial exploration . At the time of allograft 
nephrectomy, the patient's peritoneal cavity was again explored and appeared to 
be totally tumor-free exeept for an area of small bowel adjacent to an anastomosis 
which felt thickened. This area was resected with a primary anastomosis (Fig. 18 
displays a regenerating mucosa l epithelium with . residual cells throughout the 
bowel wall in the specimen taken during the second resection procedure). The 
plasmaeytie nature of the cells is seen in Fig. 19. Again , immunoperoxidase staining 
of intracytoplasmic immunoglobulins from 3 separate sites revealed marked 
restriction of the mature plasma cells to expression of lambda light chain (Figs. 20, 
21). The process was interpreted pathologically as resolving lymphoproliferative 
lesions , both grossly and microscopically. Immunosuppression was obviously 
stopped completely at this time due to allograft nephrectomy and the patient 
recovered uneventfully. Five years later he remains well and free of tumor (Fig . 22) 
Fig. 26. CT scan investigation of the epigastric mass depicted in Fig. 25, further defining a largc , solid , 
non-invading mass anteriorly in the epigastrium . CT studies proved to be an excellent method of 
following the lesion . 
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and awaits a new kidney transplant after having been placed back on our candidate 
list. 
Case 4: This 4-year-old male underwent an uneventful orthotopic liver transplant 
for biliary atresia with failed Kasai procedure. His post-operative course was 
smooth and he left the hospital with excellent function 7 weeks later (Fig. 23). Two 
years thereafter he presented to his local hospital with a painful and tender right 
lower quadrant mass which was suspected of being a periappendiceal abscess. At 
exploration he was found to have a PTLD involving the terminal ileum. All grossly 
visible tumor was completely resected. Pathologic studies revealed a monomor-
phous proliferation of predominantly small noncleaved lymphoid cells (Fig. 24). 
Neither large atypical cells nor areas of plasmacytoid differentiation were seen. 
The tumor was monoclonal lambda by immunocytochemistry. 
Post-operatively his CsA was decreased from 5.2 mg/kg/day to no drug for 7 
days and then resumed at 2.5 mg/kg/day. Prednisone was decreased from 20 to 
5 mg/day. He did well initially, but 5 months later he developed a large epigastric 
mass involving the small bowel mesentery. Radiographic studies are presented in 
Figs. 25 and 26. All immunosuppression was completely stopped for 3 months. The 
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Fig. 27. Schematized representation of flow cytometric analysis of case 4. Leu 14-positive cells 
represented 62.8% of the population. Leu 4 (11.6%), lambda (38.4'%), kappa (6.0%), and Dr (19%) 
antigens are also represented. 
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patient developed a refractory hypercalcemia (17 mg/dl) and there was no change 
in tumor size. At 8 months after the initial diagnosis of PTLD was made, he 
underwent an almost complete excision of the large epigastric PTLD, which was 
favorably situated on the mesentery. Histopathology showed a lesion identical to 
the first occasion. Flow cytometry (Fig. 27) showed the tumor to again demonstrate 
clonal restriction for lambda light chain. Currently, at about 1 month following his 
latest resection, he is normocalcemic and progressing well, off all immunosuppres-
sion, with no gross evidence of tumor and with very reasonable liver functions. 
Case 5: This 34-year-old male underwent an orthotopic liver transplant for end-
stage liver disease secondary to sclerosing cholangitis associated with Crohn's 
disease. He promptly recovered and was discharged in 4 weeks. Approximately 5 
months after transplantation, the patient returned complaining of malaise, 
anorexia and fever (Fig. 28). Work-up revealed marked inguinal and 
retroperitoneal lymphadenopathy (Fig. 29). Operative biopsies revealed a poly-
morphous PTLD characterized by areas of necrosis and numerous atypical large 
cells, some resembling Reed-Sternberg cells. The cellular background contained 
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Fig. 28. Post-operative course of a 32-year-old male liver transplant recipient who presented with 
generalized lymphadenopathy and Hodgkin's-type PTLD, requiring marked reduction in immunosup-
pression and radiation for control, and who rejected his liver requiring retransplantation. 
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significant numbers of lymphocytes and eosinophils, leading to a diagnosis of 
Hodgkin's disease. EBV genome was demonstrated within the tumor by DNA 
hybridization. Immunocytochemical analysis of immunoglobulins revealed a poly-
clonal pattern. Whether this represents a bona fide case of Hodgkin's disease or is a 
variant of PTLD is currently under investigation. 
The patient's immunosuppression was significantly reduced, CsA from 7.5 to 
3.3 mg/kg/day and prednisone from 17.5 to 10 mg/day. No response was observed 
and he subsequently received a course of radiotherapy. Remission followed 
immediately, but the patient underwent severe rejection requiring retransplanta-
tion. There was no evidence of residual tumor at the time of his second liver 
transplant. He remains well, with normal liver function and no evidence of tumor 
almost 2 years later. 
Case 6: This 43-year-old male was admitted with end-stage liver disease 
secondary to Laennec's cirrhosis and hepatorenal syndrome. He underwent 
orthotopic liver transplantation, followed by an extremely stormy post-operative 
course. This was characterized by severe renal failure, fungemia, several episodes 
of rejection and, in general, very slow recovery. However, he slowly improved and 
was discharged from the hospital with good hepatic and renal function (Fig. 30). Six 
months after transplantation, the patient was admitted to his local hospital with 
shortness of breath and a productive cough. Pneumocystis carinii pneumonia 
(PCP) and disseminated cytomegalovirus (CMV) infection were diagnosed 
(Fig. 31). CsA therapy was stopped (5.5 to 0 mg/kg/day) and prednisone was 
decreased from 7.5 to 5 mg/day (Fig. 30). He also received trimethoprim sul-
famethoxazole therapy, required ICU care and intubation with respiratory 
support. He slowly improved and his chest picture resolved significantly except for 
a persistant, peculiar nodular infiltrate which was evident on chest X-ray (Fig. 32) 
and CT scan (Fig. 33). He underwent an open lung biopsy of one of the suspicious 
areas which revealed a monomorphous PTLD (cf. Fig. 4). Immunosuppression was 
completely stopped and the patient's chest pathology resolved completely 
(Fig. 34). He was discharged on low maintenance immunosuppression, and at the 
present time, approximately 7 months later, he is stable, clinically tumor-free and 
maintains good liver function. 
Kaposi's sarcoma 
Introduction 
Kaposi's sarcoma is a rare form of tumor in the general population, particularly 
in the Western hemisphere, although its incidence is higher in populations of 
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Fig. 29. CT sca n of the abJomen demonstra ting pe riaorti c en larged nodes as part of the genera lized 
lymphadenopathy of thi s patient's presentation. 
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hg. 31. Chest x-ray demonstratin~ severe white-out of the lungs represlO nling PCP, CMV pneumonitis 
and PTLD of the lung with respiratory failure. 
Mediterranean and Jewish ancestry and in certain regions of Africa (40). In the last 
decade there has been a sharp increase in the incidence of this tumor as a result of 
the spread of AIDS (41). 
Another group that is at high risk for development of Kaposi's sarcoma is 
represented by the allograft transplant population . This lesion has been seen with 
hg . 32. hest x-ray demonstrating a persistent, peculiar nodular infiltrate which was dia~nosed as 
PTLD on open lun~ biopsy. 
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Fig. 33 . CT scan of chest further demonstrating and de linct1ting these peCllliar, persistent lesions seen 
on chest x-ray. 
Fig. 34 . hest x-ray prior to patient 's discharge (kmonstrating complett; resolution of the PTLD of the 
lung. 
much less frequency than PTLDs in our series . Nevertheless, striking similarities in 
therapeutic response lead us to believe that analogous host mechanisms may be at 
work in both types of disorders. 
Etiology 
The etiology of this unusual form of sarcoma is stillullknown, although an ever 
expanding body of knowledge seems to suggest certain associated factors. Several 
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studies performed in various centers around the world have shown a correlati,on 
between the development of Kaposi's sarcoma and depressed immune system 
states. The T4ffS ratio is depressed in these patients, although this does not appear 
to be a prerequisite for the development of this tumor (41). The presence of CMV 
infection as documented by serologic studies is almost the rule (41). The infection 
does not necessarily need to be de novo. Previous exposure with reactivation of 
"dormant" virus seems to be the case in a good number of patients (41). The 
scenario that is most often postulated is that of a debilitated immune system 
attacked by CMV, with the virus somehow inducing or contributing to the 
formation of Kaposi's sarcoma. 
Presentation and course 
Kaposi's sarcoma may present as characteristic purplish, raised, firm and non-
tender skin lesions. A more widespread form of the disease may involve the 
gastrointestinal tract, lungs, and/or lymph nodes. The skin lesions are normally 
asymptomatic, but the gastrointestinal involvement may cause such severe 
symptoms as nausea, vomiting, abdominal pain, loss of appetite or hemorrhage. 
Fever and weight loss may also occur. Concomitant infections, particularly with 
candida, are not infrequent. Left alone, the disseminated form of the disease will 
progress to cachexia and death. 
Table 6. Kaposi's sarcoma in kidney transplant recipients. 
Case Sex Age (yr) Date Time (Mo) Involvement Clinical CMV 
atTx ofTx of onset presentation infection 
of sarcoma 
after Tx 
1 M 59 Nov. 2, 3 Diffuse cutaneous Skin lesions of Reactivation 
1981 arms. legs and 
penis 
2 M 51 Dec. 3, 10 Diffuse cutaneous Skin lesions of Reactivation 
1982 forearm + penis 
3 M 34 Sept. 22. 6 Diffuse cutaneous, Skin lesions Reactivation 
1985 diffuse GI arising initially 
around operative 
Incision and then 
diffuse: severe 
GI symptoms 
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Fig. 35. Post-operative course of a 35-year-old male kidney recipient who developed diffuse Kaposi's 
sarcoma of the skin and GI tract requiring complete cessation of immunosuppression for relative tumor 
control although the kidney is being slowly rejected. 
Con tempo- Original Change in Other anti- Fate of patient Graft 
raneous Immuno- immunosuppres~ion tumor treatment function 
infection suppression C,;\ Prednisone 
(mg/kg/d) (mg/d) 
None C\;\. Pred 14-1.35 10-10 None Died 5/16/86. after Rejected, 
Rc-KTx Re-KTx 
(Systemic TB and 
J .isteria 
meningitis) 
None esA. Pred 9.8-2.5 15-10 Radiation Alive with new Retained 
skin lesions: to date 
receiving low 
dose esA 
----
None esA. Pred 4.2-0 15-0 None Alive in complel" remis- Retained 
sion ;-re-institution to date; but 
of low dose CsA + slowly being 
prednisone led to rapid rejected 
tumor recurrence which 
resolved when CsA dis-
continue-d. 
-----
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Fig . ,16. Typical skin lesions of Kapusi's sarcoma <!round the transplant scar. 
Patient population 
We have identified 3 patients (O.l 'X,) in our entire transplant population who 
have developed Kaposi's sarcoma following kidney allografting (Table 6), Thus, 
Kaposi's sarcoma accounts for 7.7()/(), and PTLO for 92.3 % of our total tumor 
population, This proportion is in keeping with rece nt published figures (17). 
All 3 patients were male, received kidney transplants , and were Saudi Arabian 
in origin. All 3 had evidence of reactivated CMV infection. 
Case Rcport of Kaposi's sarcoma paticnt 
This 35-year-old Saudi male underwent a eauaveric kiuney transplant for end-
stage renal disease (Fig. 35). The allograft had immediate and sustained function . 
Prior to transplantation, he had been found to be PPO positive and had rece ived 
prophylactic anti-tuberculin the rapy. Post-transplant he developeu schistosomiasis 
of the bladder and epididymitis, both of which were satisfactorily treated. Six 
months post-transplant, he deve loped purplish, raised skin lesions aro und the 
transplant scar (Fig. 36), with subse4L1ent dissemination to the ches t and upper 
arms (Fig.37). A skin biopsy of one of the allograft Scar lesions d emonstrated 
Kaposi's sarcoma. He rapidly developed severe gastrointestinal symptoms and was 
found to have diffuse involvement of the GI tract by UGI series (Figs. 38. 39), This 
was confirmed by endoscopic biopsy. Histologic examination of the biopsy showed 
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Fig. 37 . Typical skin lesions of Kaposi's sa rcoma OIl the arm. These ksions were (Iiffuse. 
Fig,3H. Small bowel scries de mo nstrating diffuse widespread involve meIlt o f GI tract with Ka posi's 
sarcoma (b io psy proven), Arrows ci c Jl1 om; tra te thick , infiltrated ru ga l folds with tUlllor. 
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Fig. 39. Close-up of smilll bowel s~ril!s ubove, demonstrating the prominent folds in stomach infiltrated 
with tumor. 
a characteristic proliferation of spindle cells which formed vascular slits containing 
erythrocytes (Fig. 40). The appearance w?s similar to that of the skin biopsy. 
Complete cessation of immunosuppressive therapy (Fig.35) led to rapid 
resolution of the lesions, evidenced mQst dramatically in the GI tract (Fig. 41). A 
reduction of the number and size of the skin lesions also occurred. The patient 
maintained relatively good renal function even without immunosuppression. An 
attempt to restart low dose immunosuppression with CsA and prednisone led to a 
Fig. 40. Kaposi's sarcoma in il gastri" biopsy of the kidney transplant recipient. A proliferation of 
spindle cells forms vasculur slits which contain red cells. In one ~nd of the photograph glandular 
epithel'fullI is present (H and E). 
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Fig. 41 . Follow-up GI series after complete discontinuation of immunosuppression and resolution of GI 
symptoms demonstrates normal mucosal pattern and no evidence of Kaposi's sarcoma. 
rapid reappearance of the skin lesions and GI symptoms. Consequently, the 
immunosuppression was again terminated, again with resolution of the lesions. 
The kidney graft continues to function 10 months later, but an increase in the 
allograft size and creatinine indicate slow, progressive renal rejection . The patient 
remains relatively well with minimal remaining lesions of the skin and no evidence 
of gastrointestinal lesions . 
Discussion 
The spectrum of Iymphoproliferations occurring in post-transplant immunosup-
pressed patients and associated with the Fpstein-Barr virus has been recognized for 
several years. PENN has recently estimated that PTLDs constitute 4] % of all 
tumors occurring in patients immunosuppressed with CsA, in contrast to 12% of 
tumors in conventionally immunosuppressed allograft recipients (17). Our current 
report is based on the largest single series of CsA-immunosuppressed individuals to 
date. 
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The favorable outcome of a significant number of these cases in response to 
modulation of immunosuppression has raised the challenge, of defining both host 
and tumor variables that characterize the mechanisms and limitations of immune 
controls in this system. We have presented evidence that most polyclonal and many 
monoclonal tumors remain subject to host control mechanisms if immune function 
is allowed to recover at least partially by a reduction of immunosuppressive 
therapy. This observation indicates that a diagnosis of monoclonallymphoprolifer-
ation in and of itself is not equivalent to a diagnosis of malignant lymphoma in 
these patients. 
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Fig. 42. Suggested pathogenetic sequence of PTLDs. See text for Discussion. 
Our current concept of the pathogenesis of this disorder is indicated in Fig. 42. 
This represents an extension from that previously published (42). EBV infects the 
B-Iymphocyte and causes a poly clonal proliferation of cells. In cases of infectious 
mononucleosis occurring in non-immunosuppressed hosts, this normally leads to 
very early plasmacytic maturation, induced by a variety of lymphokines. The fate 
of these cells is currently unknown. They are dispersed early from the circulation 
and in their place are seen infected cells that do not display the appearance of 
plasma cclls. Thesc are designated as residual cells in the diagram and arc 
themselves dispersed by a variety of mechanisms, in particular by cytotoxic T-cells. 
Again, the extent and range of long-term survival of this residual cell type is poorly 
characterized. 
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In immunosuppressed transplant recipients, a similar sequence of events may 
occur. Indeed, it is likely that somc of our patients sustain an illness identical to 
normal or subclinical infectious mononuclcosis, since the frequency of primary and 
reactivation infection exceeds the number of PTLDs. In other cases, iatrogenic 
immunosuppression may allow time for clonal sclection processes to operate. This 
may result in the overgrowth of one or several clones, resulting in a multiclonal or 
monoclonal proliferation. Whether this process represents a response to external 
antigenic stimulation or events indigenous to the cell clone in question is not at 
present answerable. Both processes appear equally likely. 
This form of monoclonal proliferation, although poorly controlled and histologi-
cally invasive, is probably still amenable to reconstituted host immune control 
mechanisms. We suggest that clinical regression is accompanied by a maturation of 
cells into plasma cells with subsequent dispersal and organ repair. This would 
appear to be the sequence of events followed by the tumor in case 3. We have 
observed similar clinical behavior in other monoclonal tumors restricted to gut or 
lungs. It is possible that monoclonal tumors restricted to single organs arc 
especially responsive to immunomodulation. 
It is not yet clear at what point, if any, reconstitution of the immune system can 
no longer switch off tumor growth. Deaths both of patients with polyclonal and 
monoclonal tumors have seemed more related to the lateness of diagnosis than to 
any other factor. It is possible but difficult to prove at the moment that some of the 
patients who died had tumors which had sustained an irreversible change or 
changes conferring complete autonomy and metastatic potential (Fig. 42) but at 
present, the specific critical change remains undefined. 
One example of a tumor which we consider to be more than a benign lesion but 
somewhat less than a fully developed malignancy is that of case 4. This recurrent 
neoplasm manifested a karyotypic translocation and has not completely regressed 
in the absence of immunosuppression (NALESNIK et aI., manuscript in preparation). 
Despite its large size and multiple recurrences, it has not demonstrated metastatic 
potential. The prolonged survival of this patient as compared to similar cases in the 
literature argues that the therapeutic dilemma has been successfully handled to 
date. 
We consider polyclonal proliferations to be at the more benign end of the 
spectrum of PTLDs. However, occasional patients exhibit an explosive onset of 
widespread polyclonallymphoproliferation with an acute course that often leads to 
death before the diagnosis can be established. At our current level of knowledge 
we presume that this represents an exaggerated host defect in the handling of the 
Epstein-Barr virus infection. 
The instinctive approach to the treatment of the PTLDs would be 
chemotherapy. However, based on our clinical results the more logical initial 
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therapy appears to be manipulation of the immune system. A drastic reduction or 
even complete cessation of immunosuppressive therapy elicits a rapid response in 
those cases amenable to this therapy. Interestingly enough, rejection did not occur 
in some of our cases even if the immunosuppression was reduced to up to 75% of 
the initial dose (18). Therefore, in practice we generally assess the clinical response 
to a 50% reduction of immunosuppressive therapy. The remission is usually 
complete and the immunosuppressive regimen may later be resumed at previous or 
reduced levels. The temptation to treat with chemotherapy should be resisted since 
this would further reduce the host immune response, causing an even worse 
exacerbation of PTLD. In those monoclonal and monomorphous tumors which do 
not respond to a reasonable trial of reduced immunosuppression, aggressive 
antilymphoma therapy may be unavoidable. In practice, these unfortunate patients 
are usually moribund at the outset, have a very rapid downhill course, and often 
die with multiple infections. Add to this the fact that there is still no absolute 
a priori pathologic indicator of which tumors will and which will not respond to 
host immune restoration in a given patient. the case for immunosuppressive dose 
modulation as an initial therapy appears complete. 
Comments regarding Kaposi's sarcoma must be even more preliminary, 
considering the low frequency of this lesion in our population. Based on the 
behavior of this tumor in our series, the possibility exists that this condition may 
also represent an as yet unrecognized spectrum of disorders. The hypothesis that 
Kaposi's sarcoma may be a reversible hyperplasia has long been suspected (13, 24, 
27, 43). This argument is based on the following observations: 1) the lesion has a 
male: female ratio of 15 : 1, implying a hormone-responsive factor in pathogenesis, 
2) the lesion often appears in "crops", a behavior unusual for de novo neoplasms, 
3) an 84% rate of regression in transplant patients following reduction of 
immunosuppression is claimed, 4) no well-defined cluster of neoplastic cells is 
observed in early lesions, 5) tumor emboli are not seen in sites of presumed 
metastases, 6) sites of extracutaneous involvement are readily predictable. The 
persistence of skin lesions in our case, accompanied by the disappearance of 
histologically identical gastrointestinal lesions, indicates that our current classifica-
tion of this disorder is inadequate. 
Many basic questions regarding oncogene activation, viral integration into host 
genome, specific host immune defects. etc. remain to be answered. Continued 
analysis of these lesions in our patients and in similar patients from other 
institutions, as well as animal model studies, will continue to lead to important 
insights into these interesting disease processes. 
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